Despite a narrowly negative advisory committee vote, the FDA approved UroGen’s hydrogel formulation for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer based on high response rates and durable efficacy. This non-surgical option aims to reduce the need for repeated surgeries, representing an important advance for patient care and quality of life.